multiple sclerosis monoclonal antibody therapy (Bird Rock Bio)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namemultiple sclerosis monoclonal antibody therapy (Bird Rock Bio)
Drug Alias Namemultiple sclerosis monoclonal antibody therapy (RuiYi)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionG-protein coupled receptor modulators
TargetsG-protein coupled receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBird Rock Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBird Rock Bio Inc
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A